SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Gross Profit
SCI Pharmtech Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Gross Profit
NT$383.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-2%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Gross Profit
NT$3.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Gross Profit
NT$2B
|
CAGR 3-Years
28%
|
CAGR 5-Years
19%
|
CAGR 10-Years
11%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Gross Profit
NT$1.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-3%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Gross Profit
NT$9.9B
|
CAGR 3-Years
21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
24%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Gross Profit
NT$2.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Gross Profit?
Gross Profit
383.2m
TWD
Based on the financial report for Sep 30, 2024, SCI Pharmtech Inc's Gross Profit amounts to 383.2m TWD.
What is SCI Pharmtech Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
-2%
Over the last year, the Gross Profit growth was 5%. The average annual Gross Profit growth rates for SCI Pharmtech Inc have been -4% over the past three years , -16% over the past five years , and -2% over the past ten years .
You don't have any saved screeners yet